Ocrelizumab

Resumen

Alternativas con registro en Colombia

• Natalizumab · costo anual estimado $ 70.535.885
• Belimumab · costo anual estimado $ 31.779.820
• Vedolizumab · costo anual estimado $ 82.013.310
• Alemtuzumab · costo anual estimado $ 23.383.597.615
• Inebilizumab
• Anifrolumab · costo anual estimado $ 49.469.545
• Teprotumumab

Estudios clínicos principales

• Operetta 2: A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RR
  Fase 3 · 2022 · 188 participantes · Hoffmann-La Roche · NCT05123703
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
  Fase 3 · 2017 · 1.225 participantes · Hoffmann-La Roche · NCT03085810
• O'HAND: A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
  Fase 3 · 2019 · 1.013 participantes · Hoffmann-La Roche · NCT04035005
• Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multip
  Fase 3 · 2016 · 131 participantes · Genentech, Inc. · NCT02688985

Enfermedades relacionadas

• Esclerosis múltiple

Fuentes

• Etiqueta FDA (DailyMed): OCREVUS
• EMA: Ocrevus